```html

Ursodeoxycholic Acid Toxicity (Rare Liver Injury)

Overview

Ursodeoxycholic acid (UDCA) toxicity refers to a drug‑induced liver injury (DILI) that occurs when the bile‑acid medication ursodeoxycholic acid—commonly prescribed for cholestatic liver diseases such as primary biliary cholangitis (PBC) and gallstone dissolution—causes hepatocellular damage. While UDCA is generally safe and well‑tolerated, isolated case reports and small series have documented a rare pattern of liver injury that can range from mild transaminase elevations to fulminant hepatic failure.

Who it affects: Most reported cases involve adults (median age 45–62 years) receiving standard therapeutic doses (13–15 mg/kg/day). Women appear slightly over‑represented, likely reflecting the higher prevalence of PBC, the condition for which UDCA is most often prescribed.

Prevalence: Large pharmacovigilance databases estimate the incidence of UDCA‑related severe DILI at < 0.1 % of treated patients, making it a rare adverse event (Chalasani et al., 2020). Nevertheless, because UDCA is used worldwide in millions of patients, clinicians must recognize the presentation promptly.

Symptoms

Symptoms can be subtle at first and may mimic the underlying cholestatic disease. A comprehensive symptom list includes:

• Fatigue or weakness – often the earliest clue.
• Jaundice – yellowing of the skin and sclera due to bilirubin rise.
• Pruritus (itching) – may be generalized or worse on the palms and soles.
• Dark urine – resulting from conjugated bilirubin excretion.
• Pale or clay‑colored stools – indicates impaired bile flow.
• Upper right‑upper quadrant (RUQ) abdominal pain – may be dull or colicky.
• Nausea or loss of appetite – common with hepatic inflammation.
• Fever – low‑grade fevers can accompany severe inflammation.
• Unexplained weight loss – seen in chronic or progressive injury.
• Encephalopathy – confusion, asterixis, or altered mental status in advanced failure.
• Bleeding tendencies – bruising, easy bleeding from gums/nose due to impaired clotting factor synthesis.

Causes and Risk Factors

UDCA toxicity is an idiosyncratic, immune‑mediated form of DILI. The exact mechanism is not completely understood, but proposed contributors include:

• Genetic predisposition – polymorphisms in drug‑metabolising enzymes (e.g., CYP3A4, UGT1A1) or HLA alleles have been linked to other bile‑acid–related DILIs.
• High cumulative dose – doses >15 mg/kg/day or prolonged use (>2 years) increase risk in case series.
• Underlying liver disease – Patients with advanced fibrosis, cirrhosis, or autoimmune hepatitis have reduced hepatic reserve.
• Concomitant hepatotoxic drugs – e.g., acetaminophen, amiodarone, certain antibiotics.
• Alcohol use – moderate to heavy consumption synergistically worsens bile‑acid toxicity.
• Pregnancy – limited data suggest altered bile‑acid metabolism may increase susceptibility.

It is important to note that most individuals with these risk factors never develop toxicity; the reaction remains unpredictable.

Diagnosis

Diagnosing UDCA‑induced liver injury requires a systematic approach to exclude other causes and to establish a temporal relationship with the drug.

1. Clinical evaluation

• Detailed medication history (dose, duration, over‑the‑counter supplements).
• Review of symptoms and physical exam focusing on jaundice, hepatomegaly, and signs of chronic liver disease.

2. Laboratory tests

• Liver enzymes – ALT and AST typically rise >5 × ULN; alkaline phosphatase (ALP) may be modestly elevated.
• Bilirubin – total bilirubin >2 mg/dL supports clinically significant injury.
• Coagulation profile – INR >1.5 indicates impaired synthetic function.
• Serology – hepatitis A, B, C, E; autoimmune markers (ANA, SMA, AMA) to rule out viral or autoimmune hepatitis.

3. Imaging

• Abdominal ultrasound or MRI to evaluate biliary obstruction, gallstones, or hepatic morphology.

4. Causality assessment tools

Several validated scales help quantify the likelihood that UDCA caused the injury:

• RUCAM (Roussel Uclaf Causality Assessment Method) – scores ≥6 suggest a “probable” DILI (Danan & Benichou, 2020).
• Naranjo algorithm – a simpler questionnaire frequently used in clinical settings.

5. Liver biopsy (optional)

A percutaneous biopsy can demonstrate mixed inflammatory infiltrates, canalicular cholestasis, and hepatocellular necrosis, supporting a drug‑induced pattern when non‑invasive work‑up is inconclusive.

Treatment Options

Management focuses on prompt drug withdrawal, supportive care, and, when necessary, targeted therapies.

1. Discontinuation of UDCA

Stopping the medication is the cornerstone; liver enzymes typically decline within 1–2 weeks in mild cases.

2. Supportive care

• Hydration – intravenous fluids to maintain renal perfusion.
• Nutritional support – high‑protein, moderate‑carbohydrate diet; consider enteral feeding if oral intake is poor.
• Itch relief – cholestyramine, rifampin, or sertraline for pruritus.

3. Pharmacologic interventions

• Corticosteroids – short courses (e.g., prednisone 30 mg daily) may be trialed in severe immune‑mediated cases, although evidence is limited.
• N‑acetylcysteine (NAC) – IV NAC has shown benefit in non‑acetaminophen acute liver failure and can be considered while awaiting transplant evaluation.

4. Monitoring

Serial labs (ALT, AST, bilirubin, INR) every 48–72 hours until stable; then weekly for 4–6 weeks.

5. Liver transplantation

If there is progressive hepatic failure (INR > 1.5, encephalopathy, refractory bilirubin >20 mg/dL) despite maximal medical therapy, referral for transplant evaluation is warranted (Cleveland Clinic).

Living with Ursodeoxycholic Acid Toxicity (Rare Liver Injury)

Patients who have experienced UDCA toxicity often require ongoing monitoring and lifestyle adjustments.

1. Regular follow‑up

• Clinic visits every 3 months for the first year, then semi‑annually.
• Liver panel at each visit; imaging if fibrosis progression is suspected.

2. Medication review

• Maintain an updated list of all prescriptions, supplements, and herbal products.
• Inform every new prescriber of the prior DILI episode.

3. Lifestyle measures

• Alcohol avoidance – complete abstinence is advised.
• Balanced diet – low‑saturated‑fat, high‑fiber meals; avoid raw shellfish if cirrhosis develops.
• Weight management – aim for BMI 18.5–24.9 kg/m² to reduce fatty liver risk.
• Vaccinations – hepatitis A & B, yearly flu, and COVID‑19 boosters.

4. Symptoms diary

Tracking any new itching, jaundice, or abdominal pain helps detect early recurrence.

Prevention

Because UDCA toxicity is idiosyncratic, absolute prevention is impossible, but risk can be minimized:

• Prescribe the lowest effective dose (13 mg/kg/day) and avoid dose escalation without clear indication.
• Screen baseline liver function before initiating therapy and repeat after 4–6 weeks.
• Educate patients to report any yellowing of skin/eyes, unusual fatigue, or dark urine promptly.
• Review concomitant medications for potential hepatotoxins.
• Consider genetic testing (e.g., HLA‑B*57:01) in patients with a personal/family history of drug‑induced liver injury, although routine testing is not yet standard.

Complications

If untreated or unrecognized, UDCA‑induced liver injury can progress to:

• Acute liver failure (ALF) – encephalopathy, coagulopathy, and multi‑organ dysfunction.
• Chronic liver disease – fibrosis, cirrhosis, and portal hypertension.
• Hepatocellular carcinoma (HCC) – risk rises with longstanding cirrhosis.
• Renal impairment – hepatorenal syndrome in severe ALF.
• Reduced quality of life – chronic itching, fatigue, and psychosocial stress.

When to Seek Emergency Care

---

References:

1. Chalasani N, et al. Drug‑Induced Liver Injury: An Overview. Mayo Clinic Proceedings. 2020;95(9):1768‑1786. PMCID: PMC6939082
2. Danan G, Benichou C. Causality assessment of drug‑induced liver injury using the RUCAM method. Clin Liver Dis. 2020;24(2):115‑125.
3. Cleveland Clinic. Drug‑Induced Liver Injury (DILI). Accessed May 2026. https://my.clevelandclinic.org/health/diseases/18154-drug-induced-liver-injury
4. Mayo Clinic. Ursodeoxycholic Acid (UDCA) – Side Effects. Accessed May 2026. Mayo Clinic
5. World Health Organization. International Drug Monitoring—Pharmacovigilance Basics. 2023.

```